NeogenTC
PrivateLast Round
Series B
Feb 1, 2024
Total Funding Raised
$19.52M
Company Overview
NeogenTC operates in Healthcare & Life Sciences and is based in Seoul. Its latest recorded funding round was a Series B round in February 2024.
NeogenTC is a biotechnology company that develops personalized anti-cancer immune T-cell therapies based on a novel antigen discovery platform.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
NeogenTC Comparables
Compare NeogenTC with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Shanghai Juncell Therapeutics Co., Ltd. | 87% | |
| Grit Biotherapeutics | 86% | |
| Obsidian Therapeutics | 83% |
For institutional investors. Book with your work email.
NeogenTC Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Feb 1, 2024 | ||||
| Series A | Apr 6, 2021 | ||||
| Seed | Dec 1, 2020 |
For institutional investors. Book with your work email.
NeogenTC Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Seoul Investment Partners | Series A |
| DSC Investment | Series A |
| Bluepoint Partners | Seed |
| TS Investment | Series A |
| LogInvestment | Series A |
| Tcha Partners Asset Management | Series A |
| QUAD Ventures | Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 3, 2026
Monthly visitors increased 79% to 3,000.
- Jun 1, 2025
Monthly visitors increased 42% MoM.
For institutional investors. Book with your work email.
NeogenTC Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about NeogenTC's valuation, stock price, and market status.
Is NeogenTC a public or private company?
NeogenTC is a private company.
What is the current stock price of NeogenTC?
NeogenTC is a private company, so its shares have no public market price. Caplight tracks NeogenTC's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is NeogenTC worth (valuation)?
Valuation information for NeogenTC is not publicly available.
Can I buy NeogenTC stock?
NeogenTC shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was NeogenTC's last funding round?
NeogenTC's most recent funding round was Series B on February 1, 2024.
Who are the main investors in NeogenTC?
Key investors in NeogenTC include Seoul Investment Partners, DSC Investment, Bluepoint Partners, TS Investment, LogInvestment.
Will NeogenTC IPO soon?
No public IPO plans have been announced for NeogenTC.
How can I track NeogenTC secondary market activity?
Caplight tracks bids, offers, and trades in NeogenTC's shares on secondary markets.